seen from Italy
seen from United States
seen from Malaysia
seen from Maldives
seen from United States
seen from Brazil
seen from Malaysia
seen from China
seen from Malaysia
seen from United States
seen from China
seen from Philippines
seen from United States
seen from Malaysia
seen from United Kingdom
seen from Malaysia
seen from United States
seen from China
seen from China
seen from Singapore
Cipla sees weight-loss drugs as the biggest opportunity in the Indian market
Drugmaker Cipla Ltd anticipates GLP-1 drugs, used for treating type-2 diabetes and obesity, to be a definite new therapy in the Indian market, and is exploring a wider foray, said chief executive Umang Vohra. “The Indian market is particularly important to us, where we’re looking at the whole GLP-1 category and not just Semaglutide alone,” Vohra told reporters in a media interaction on Friday…
Cipla Q3 Profit Dips 2.6% To Rs 729 Crore
Cipla Q3 Profit Dips 2.6% To Rs 729 Crore
Cipla’s net profit for third quarter witnessed a slide New Delhi: Drug major Cipla on Tuesday reported a 2.6 per cent decline in its consolidated profit after tax to Rs 729 crore for the third quarter ended on December 31, 2021. The Mumbai-based company had posted a consolidated profit after tax (PAT) of Rs 748 crore in the October-December quarter of 2020-21 fiscal. Total revenue from…
View On WordPress
